ALTB-268 Ulcerative Colitis Trial: Early Signal, Key Limits
ALTB-268 ulcerative colitis trial: AltruBio reports 23.1% week 12 remission on the higher dose in a small open-label Phase 2a. Still investigational.
ALTB-268 ulcerative colitis trial: AltruBio reports 23.1% week 12 remission on the higher dose in a small open-label Phase 2a. Still investigational.